1. Home
  2. JKS vs PHVS Comparison

JKS vs PHVS Comparison

Compare JKS & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo JinkoSolar Holding Company Limited (each representing 4)

JKS

JinkoSolar Holding Company Limited (each representing 4)

HOLD

Current Price

$29.73

Market Cap

1.4B

Sector

Technology

ML Signal

HOLD

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$24.93

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JKS
PHVS
Founded
2006
2015
Country
China
Switzerland
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.7B
IPO Year
2010
2021

Fundamental Metrics

Financial Performance
Metric
JKS
PHVS
Price
$29.73
$24.93
Analyst Decision
Sell
Buy
Analyst Count
4
9
Target Price
$19.49
$39.44
AVG Volume (30 Days)
679.0K
240.7K
Earning Date
11-17-2025
11-12-2025
Dividend Yield
4.41%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$9,641,756,390.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$36.76
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.42
$11.51
52 Week High
$31.88
$29.80

Technical Indicators

Market Signals
Indicator
JKS
PHVS
Relative Strength Index (RSI) 60.70 47.90
Support Level $26.51 $25.28
Resistance Level $30.90 $26.68
Average True Range (ATR) 1.36 1.53
MACD 0.19 -0.07
Stochastic Oscillator 76.94 29.94

Price Performance

Historical Comparison
JKS
PHVS

About JKS JinkoSolar Holding Company Limited (each representing 4)

JinkoSolar Holding Co Ltd is engaged in the photovoltaic industry. The firm has built a vertically integrated solar power product value chain, manufacturing from silicon wafers to solar modules. It sells solar modules under the JinkoSolar brand. The company's products include Silicon wafers, Solar cells, and Solar modules. Its geographical segments are China (including Hong Kong and Taiwan), North America, Europe, Asia Pacific, and the Rest of the world.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

Share on Social Networks: